Antimicrobial photodynamic inactivation (aPDI) uses photosensitizers (PSs) and harmless visible light to generate reactive oxygen species (ROS) and kill microbes. Multidrug efflux systems can moderate the phototoxic effects of PSs by expelling the compounds from cells. We hypothesized that increasing intracellular concentrations of PSs by inhibiting efflux with a covalently attached efflux pump inhibitor (EPI) would enhance bacterial cell phototoxicity and reduce exposure of neighboring host cells to damaging ROS. In this study, we tested the hypothesis by linking NorA EPIs to methylene blue (MB) and examining the photoantimicrobial activity of the EPI-MB hybrids against the human pathogen methicillin-resistant Staphylococcus aureus (MRSA). Photochemical/photophysical and in vitro microbiological evaluation of 16 hybrids carrying four different NorA EPIs attached to MB via four linker types identified INF55-(Ac)en-MB 12 as a lead. Compound 12 showed increased uptake into S. aureus cells and enhanced aPDI activity and wound healing effects (relative to MB) in a murine model of an abrasion wound infected by MRSA. The study supports a new approach for treating localized multidrug-resistant MRSA infections and paves the way for wider exploration of the EPI-PS hybrid strategy in aPDI. 
Methicillin-resistant Staphylococcus aureus (MRSA) infections have emerged as a major medical threat over the past two decades. 1 Despite a downward mortality trend in Europe, MRSA remains a major cause of serious skin and soft-tissue infections, [2] [3] [4] community-acquired pneumonia and catheter-related bloodstream infections, and is responsible for the majority of recurrent infections in immunocompromised patients. 5 Several classes of antibiotics have been used to treat MRSA infections over the years, including the topically applied mupirocin, later generation β-lactams, broad spectrum tetracyclines, linezolid, the lipopeptide daptomycin, the glycopeptide vancomycin and the recently approved lipoglycopeptides telavancin, oritavancin and dalbavancin. 6 Some of these antibiotics have, or will likely become, ineffective against MRSA due to the development of resistance, thus ensuring an ongoing need for new antibiotics and treatment strategies targeting this significant human pathogen. 7 Multidrug resistance often arises due to transmembrane efflux systems, which serve to pump noxious compounds from microbial cells. 8 Efflux systems in Gram-positive cocci (e.g.
MRSA) tend to exhibit broad and overlapping substrate specificities, with many compounds (e.g. antibiotics, monovalent and divalent biocides, intercalating dyes, quaternary ammonium salts, diamidines, biguanidines and plant secondary metabolites) acting as efflux pump substrates. 9 Efflux-mediated resistance in Staphylococci has been attributed to pumps from the chromosomally encoded Major Facilitator Superfamily (MFS: NorA, NorB, NorC, MdeA), 10 the Multi-Antimicrobial Extrusion protein family (MATE: mepA), 10 Small
Multidrug Resistance proteins (SMR: SepA) 11 and the plasmid encoded systems QacA, QacB and Tet(K). [12] [13] [14] The NorA pump has been extensively studied in S. aureus, including as a discovery target for small molecule efflux pump inhibitors (EPIs). 15 Photodynamic therapy (PDT) is a light-based technology that harnesses the combined power of visible or near-visible light and photosensitizers (PSs) to kill cells. PSs are typically non-toxic, highly conjugated aromatic molecules that exert photodynamic activity through reactions with molecular oxygen. 16 Illumination with light of a suitable wavelength and reaction of the excited-state PSs with O 2 generates reactive oxygen species (ROS) (e.g. singlet oxygen 1 O 2 and hydroxyl radicals •OH) that cause non-specific cell damage and death. While PDT has been widely explored in the treatment of cancer 17 and age-related macular degeneration, 18 antimicrobial photodynamic inactivation (aPDI) has only more recently emerged as a powerful sterilization technique and promising treatment for localized bacterial infections. 19 The phenothiazinium PSs methylene blue (MB) and toluidine blue O (TBO), for example, are used for photodynamic sterilization of blood products and aPDI oral cavity disinfection. [20] [21] [22] [23] Efflux pumps have been shown to moderate bacterial cell killing during aPDI with MB, apparently by lowering intracellular MB concentrations and associated (intracellular)
ROS. 24 This suggested that combination approaches, where MB is co-administered with a small molecule efflux pump inhibitor (EPI), should potentiate aPDI by increasing intracellular MB and associated ROS, thus triggering more damaging intracellular photodynamic reactions. Additionally, better localization of PSs to the bacterial intracellular space would reduce the damaging effects of the ROS generated in solution on neighboring host cells at infection sites, which could aid wound healing. Studies by Tegos et al.
demonstrated that combinations of NorA EPIs and MB (a well-characterised NorA substrate)
show enhanced PDI of S. aureus relative to MB alone. 25 We previously reported an efflux pump inhibitor-antibacterial hybrid strategy for addressing NorA efflux-mediated resistance in S. aureus. Phenothiazinium photosensitizers (e.g. MB) are amphipathic, planar, polycyclic aromatic cations and physicochemically similar to the quaternary ammonium aromatic alkaloid berberine. The structural and physicochemical similarities between berberine and MB, combined with the known susceptibility of both compounds to NorA-mediated efflux, 27 suggested that a NorA EPI-MB hybrid strategy might be successfully applied in aPDI of S.
aureus. We hypothesized that the hydrophobic/cationic EPI-MB hybrids would, in a similar fashion to MB, spontaneously enter S. aureus cells due to the negative membrane potential. 31 Unlike MB, however, the hybrids would resist efflux due to the attached NorA EPI. The higher resulting intracellular hybrid concentrations would amplify intracellular ROS (following illumination) leading to enhanced lethality compared to MB, whose photodynamic reactions are restricted by efflux mostly to the cell exterior (Figure 1 
UV/Visible Spectroscopy
The absorption properties of the MB chromophore in hybrids 1-16 were probed using UV/visible spectroscopy. MB shows strong absorption bands between 550-700 nm, displaying an intense maximum at λ max1 = 668 nm and a shoulder at λ max2 = 609 nm. 36 Large differences in wavelength and/or extinction coefficients at λ max1 and λ max2 for hybrids PDI and uptake studies with S. aureus isogenic NorA efflux mutants
Previous studies with knockout (NorA-, K1758), wild-type (WT, 8325-4) and overexpressing (NorA++, K2361) S. aureus isogenic NorA efflux mutants showed that NorA expression correlates with reduced PDI by MB, due to the NorA-mediated efflux reducing intracellular MB concentrations and associated intracellular ROS. 25 Three hybrids exhibiting both significant ROS production and potent PDI of the MRSA USA300 strain (i.e. 10, INF55(Ac)en-MB 12 and 14) were selected for studies with the S. aureus NorA efflux mutants to examine the effects of this pump on hybrid PDI activity.
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PDI of the S. aureus mutants was measured over the concentration range 0-160 µM at a constant light fluence. In dark control experiments, MB showed some dose-dependent toxicity at concentrations above 20 µM, especially against the NorA-and NorA++ strains.
The hybrids were generally less toxic than MB at equivalent concentrations (Supporting Information, Supplementary Figure 14) . Upon application of 652 nm red light (10 J/cm 2 ), MB (20 µM) caused a 2.9 log 10 reduction in survival of the NorA-strain, and 2.2 log 10 and 1.8 log 10 reductions in the WT and NorA++ strains, respectively (Figure 4 ), in agreement with a previous report. 24 The NorA++ strain showed a pronounced sensitivity to 10 and INF55(Ac)en-MB 12,
exhibiting an 8 log 10 reduction in survival at concentrations above 40 µM. The NorA-strain also showed high sensitivity to INF55(Ac)en-MB 12, while higher concentrations of 10 (80 µM) were required to produce an 8 log 10 reduction in this strain. The three strains were uniformly less sensitive to the INF271-based hybrid 14. The WT strain was the least sensitive towards all three hybrids at most concentrations. Cellular uptake of 10, INF55(Ac)en-MB 12 and 14 by the three S. aureus NorA mutants was examined using a fluorescence-based assay. Uptake of MB was highest in the NorA-strain (3.7 x 10 9 molecules/cell), reduced in the WT (1 x 10 9 molecules/cell) and lowest in the NorA++ strain (0.5 x 10 9 molecules/cell, Figure 5 ), consistent with susceptibility to NorA efflux. 25 Uptake of the three hybrids was similar and higher than MB in all strains. Hybrid uptake varied little among the strains despite the differences in NorA expression, suggesting that unlike MB the compounds are not susceptible to NorA efflux. 
CONCLUSIONS
The need for continuous development of new therapeutic approaches targeting MRSA is high since: (i) the evolutionary adaptability of MRSA to antibiotic pressure has proven to be a remarkably successful survival strategy for this important human pathogen 42 and (ii) use of conventional broad spectrum antibiotics is a risk factor for increasing resistance, especially in healthcare facilities. 43 Treatment of MRSA infections with antibiotics, including recently approved compounds 44 and new agents coming through the pipeline, 45 will likely afford only temporary solutions due to the inevitable development of resistance. In contrast, aPDI offers an attractive and easy-to-apply non-antibiotic alternative for treating localized MRSA infections that limits the development of resistance because of its multi-target/non-specific mode of action. aPDI approaches are predicted to have much longer effective clinical lifetimes than antibiotics. 46 In an era where there is an urgent need to identify anti-infective solutions beyond traditional antibiotics, aPDI offers extraordinary promise. Despite this, there have been surprisingly few clinical studies exploring aPDI [46] [47] [48] [49] [50] [51] [52] [53] .
This study explored the hypothesis that hybrid molecules, consisting of a NorA EPI covalently tethered to MB via a non-cleavable linker, could show increased aPDI activity relative to MB against MRSA. The hypothesis was founded on the idea that attaching the NorA EPI would increase intracellular concentrations of MB and associated intracellular ROS, leading to enhanced phototoxic effects. We predict that clinical use of such photoantimicrobials could provide effective aPDI treatments at low compound/light doses, thus reducing potential for ROS-mediated damage to host tissues. This is because concentrating ROS inside bacteria would place a protective (cell membrane) barrier between the phototoxic species and host cells. Preserving host tissues around infection sites should also provide benefits for wound healing through photobiomodulation effects. A noncoherent light source (LC122; LumaCare, London, UK) with 30 nm-band-pass filters at ranges of 652 ± 15 nm was used for illumination. The total power output from the fibre bundle was 300 mW. Plates were arranged to give irradiance of 100 mW/cm 2 . The power (P) in watts was equal to the energy (E) in joules, divided by the illumination time (t) in seconds:
Watt/cm 2 = joule/cm 2 per second A 30 sec illumination at irradiance 100 mW/cm 2 over a 3 cm 2 area provides a fluence of 1000 mJ/cm 2 , or 1 J/cm 2 . Fluence was proportionally increased by extending the period of illumination. A microplate spectrophotometer was used in "slow kinetic" mode for detecting fluorescence. For SOSG, emission was measured at 505 nm following excitation at 525 nm (2 nm monochromator band pass). For HPF, fluorescence emission was measured at 525 nm after excitation at 492 nm (2 nm monochromator band pass). Bioluminescence images were captured after each light dose. For the negative control Group A and dark controls Groups B and D, images were captured at the equivalent times postinoculation. Bioluminescence images were captured daily for 10 days following treatment to monitor clearance of the infection and daily photographs were taken (Nikon Coolpix L20 camera) to record wound healing.
A noncoherent light source (LC122; LumaCare, London, UK) with interchangeable fibre bundles and 30 nm band-pass filters (652 ± 15 nm) was used for light application.
Power output from the fibre bundle was 300 mW, with spots positioned at the required distance from animals to give an irradiance of 100 mW over the 1.0 cm 2 wound area.
Bioluminescence images were captured using a Hamamatsu Photonics KK (Bridgewater, NJ)
imaging system, 39 consisting of an intensified charge-coupled-device (ICCD), camera (C2400-30H; Hamamatsu), camera controller, imaging box, image processor (C5510-50;
Hamamatsu) and color monitor (PVM 1454Q; Hamamatsu). Mice were placed on an adjustable stage in the specimen chamber and infected areas positioned directly under the camera. Light-emitting diodes were mounted inside the imaging box to supply light for dimensional imaging. The setup allowed a grayscale background image of each mouse to be taken. Luminescence emanating from wounds was captured using an integration time of 2 min at the maximum setting on the image-intensifier control module. ARGUS software 
